All Activity

I'd personally declare that will this is the a terrific article of an wonderful man or woman, i am just very happy to discover this specific. 해외선물 개발

“Kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ethically structured care model.” By Jordan Tishler, Association of Cannabinoid Specialists A company recently declared its intention to roll out cannabis ordering kiosks in several senior-life communities in Arizona. The general idea is that residents would gain easier access to cannabis by being able to order products on the kiosk and have the product delivered right to them—kind of like online ordering but without needing a computer. But without appropriate safeguards for medical and non-medical users alike, the risk of this scheme may outweigh the benefit of greater access. The Association of Cannabinoid Specialists (ACS) strongly supports efforts to reduce access barriers for older adults who may benefit from cannabinoid-based therapies, especially those with limited transportation and mobility. A guided ordering interface that reinforces clinician-based treatment plans (aka prescriptions), clear product information and licensed dispensary sourcing is far preferable to unregulated or informal supply channels that some seniors might currently rely on. However, simply placing cannabis kiosks in independent living communities without robust clinical safeguards is not acceptable from a specialist perspective. Older adults typically have multiple comorbidities, complex polypharmacy and age-related changes in metabolism and cognition that substantially increase the risk of adverse events, drug–drug interactions and delirium. Furthermore, access to cannabis without clinical guidance leads to increased risk of misuse, dependence or addiction. Introducing a point-of-sale educational experience, even one described as “guided,” is not a substitute for individualized medical assessment, diagnosis and ongoing monitoring by clinicians trained in cannabinoid medicine. ACS welcomes the stated focus on education and clear product information at the point of ordering, including helping residents understand different product types, routes of administration and onset/duration profiles. But education delivered via kiosks or brand-affiliated educators remains inherently product- and transaction-centric, whereas proper cannabinoid care must be patient- and diagnosis-centric, integrated into the person’s full medical history, medication list and goals of care. For seniors, dose-finding, titration schedules, contraindications and deprescribing decisions cannot responsibly be handled through a consumer-facing digital interface. If cannabis kiosks are to be deployed in senior living communities, ACS believes the following elements are essential: Formal collaboration with the resident’s medical team, including communication of products, doses and changes over time, and documentation in the medical record. Access to qualified cannabinoid-trained clinicians (physicians, NPs) for pre-initiation assessment and ongoing follow-up, not just sales or brand educators. Clear protocols for referring both medical and non-medical users to, or back to, qualified clinicians for guidance and follow-up, particularly to screen for high-risk users and drug interactions, and to appropriately recommend and titrate regimens for older individuals. Transparent separation between clinical guidance and commercial interests, including clear disclosure of financial relationships and avoidance of quota-driven or upselling practices. Without these safeguards, the convenience and revenue opportunity described for dispensaries and communities risk outpacing appropriate clinical governance and patient safety protections. From ACS’s point of view, kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ethically structured care model. We encourage senior living operators, technology vendors and dispensaries to partner with cannabinoid medicine specialists to design programs where improved access and education are matched by rigorous clinical oversight, documentation and responsibility for outcomes. Jordan Tishler, MD is the president of the Association of Cannabinoid Specialists. The post Marijuana Ordering Kiosks For Seniors Present Both Opportunities And Risks (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

At Coastals 4x4, also known as the W.A. Diff Centre, we have over 120 years of combined experience working with 4×4’s and other vehicles. You get trustworthy advice and recommendations on how to improve your vehicle. Plus, we stock over 26,000 parts and all the best brands so you have everything under one roof.

A congressional committee has approved a bill aimed at protecting children online that could create complications for advertisers trying to promote legal marijuana and other regulated substances. Members of the House Energy and Commerce Committee last week passed the Kids Internet and Digital Safety (KIDS) Act, sponsored by Rep. Brett Guthrie (R-KY), the chair of the panel, in a 28-24 vote. This comes about three months after a similar proposal from Rep. Gus Bilirakis (R-FL) advanced through a subcommittee, while a Senate companion version awaits action. Under the latest legislation, online platforms would be prohibited from facilitating the “advertising of narcotic drugs, cannabis products, tobacco products, gambling, or alcohol to an individual that the covered platform knows is a minor.” The provision around drug use lists the “distribution, sale, or use of narcotic drugs, tobacco products, cannabis products, gambling, or alcohol” as risks that platforms would need to actively guard minors against. One section that was in prior iterations of the bill that seems to have been omitted from this latest version had stipulated that video streaming platforms would be required “to employ measures that safeguard against serving advertising for narcotic drugs, cannabis products, tobacco products, gambling, or alcohol directly to the account or profile of an individual that the service knows is a minor.” It’s unclear why that language was left out of the latest measure, H.R. 7757. Online platforms covered under the legislation include those that are publicly available for use, allow the creation of searchable usernames that can be followed, facilitate the “sharing and access to user-generated content,” is designed to promote engagement and uses user information to target advertising. Guthrie said in a press release that the measure’s passage represents one of the “meaningful steps forward to empower parents and protect children and teens online” the the panel has taken. “We owe it to parents. We owe it to communities. And most importantly, we owe it to the kids who are counting on us to get this right,” he said. Bilirakis said the bill is “designed to strengthen safeguards and increase transparency in the online space.” “I remain steadfast in my commitment to ensuring that children can safely navigate the digital world, while holding technology companies accountable for the platforms they operate,” he said. “Protecting our kids must always come before protecting corporate profits.” Few in the public policy space oppose the overall intent of the legislation, but some say its broad and potentially vague requirements could be difficult in practice. Shoshana Weismann, a fellow at the free-market R Street Institute, told Marijuana Moment last year when the Senate version was filed that the measure could ultimately block wide swaths of online advertising that are accessible by minors—even if the ads don’t target children, as the bill’s proponent’s suggest. “The problem is that the knowledge standard here is so loose,” she said, pointing to the bill’s definition of knowledge by platforms that they’re serving content to underage users. After last year’s Senate passage of the earlier measure—titled the “Kids Online Safety Act” (KOSA)—Jenna Leventoff, ACLU’s senior policy council and director of the civil right’s group’s national political advocacy division, said she was skeptical the legislation would pass constitutional muster. A number of states have attempted to adopt similar bills, Leventoff pointed out, and “in almost every case, a court has evaluated those laws and determined that they are likely to be unconstitutional.” “It’s extremely likely that KOSA is unconstitutional,” she said at the time,” and it makes me wonder why Congress is trying to enact something that won’t hold up in a court of law.” At the state level in 2024, Colorado’s Senate passed a bill similarly aimed at protecting minors from drug and other controversial content. But the proposal—which was later put on hold indefinitely by a House committee—drew fire from advocates such as Weismann at R Street Institute. She and other critics pointed out at the time that the bill could ban content around over-the-counter cough syrup and even, potentially, the Colorado governor’s social media posts in favor of the state’s legal psychedelics industry. Under existing regulations, states that have legalized have generally seen less cannabis consumption among young people compared to states where marijuana remains illegal, according to multiple studies. During a webinar in January, federal officials discussed the results of the latest Monitoring the Future (MTF) survey—which is supported by the National Institute on Drug Abuse (NIDA) and conducted every year for decades by the University of Michigan. Youth marijuana use is stable amid the state legalization movement, despite prohibitionist claims to the contrary, they said. And beyond that, more students are actually saying it’s harder to access cannabis and that they disapprove of occasional use. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — To reform advocates, the results of the survey reinforce the idea that creating a regulatory framework for cannabis where licensed retailers must check IDs and implement other security mechanisms to prevent unlawful diversion is a far more effective policy than prohibition, with illicit suppliers whose products may be untested and where age-gating isn’t a strictly enforced regulation. To that point, a separate federally funded study out of Canada that was released last year found that that youth marijuana use rates actually declined after the country legalized cannabis. The study was released about three months after German officials released a separate report on their country’s experience with legalizing marijuana nationwide. Back in July, federal health data also indicated that while past-year marijuana use in the U.S. overall has climbed in recent years, the rise has been “driven by increases…among adults 26 years or older.” As for younger Americans, rates of both past-year use and cannabis use disorder, by contrast, “remained stable among adolescents and young adults between 2021 and 2024.” Across the U.S., research suggests that marijuana use by young people has generally fallen in states that legalize the drug for adults. A report from the advocacy group Marijuana Policy Project (MPP), for example, found that youth marijuana use declined in 19 out of 21 states that legalized adult-use marijuana—with teen cannabis consumption down an average of 35 percent in the earliest states to legalize. The report cited data from a series of national and state-level youth surveys, including the annual MTF survey. Another survey from the U.S. Centers for Disease Control and Prevention (CDC) last year also showed a decline in the proportion of high-school students reporting past-month marijuana use over the past decade, as dozens of states moved to legalize cannabis. The post Congressional Lawmakers Approve Youth Safety Bill That Could Complicate Marijuana Businesses’ Online Outreach appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Connaught Place stands out for its energetic crowd and premium venues. In this setting, Connaught Place Escorts is frequently mentioned by those who appreciate organized companionship services that value privacy and friendly conversation.

Marijuana may be a “gateway,” but not in the stigmatized way it’s been portrayed by prohibitionists as a stepping stone to other drugs. Rather, a growing body of scientific literature signals cannabis is a “gateway to women’s orgasm” that could hold significant therapeutic potential in the treatment of female orgasmic disorder/difficulty (FOD), a new research paper says. For the analysis, published in the journal Current Sexual Health Reports last week, clinical sexologist Suzanne Mulvehill discussed how, even though FOD affects an estimated 72 percent of premenopausal women, there are currently no drugs approved by the Food and Drug Administration (FDA) to treat the condition. And cannabis represents a novel therapy that could fill that treatment gap. “Psychiatrists have traditionally been trained to define legitimate prescribing primarily through formally regulated pharmaceutical pathways, even while routinely prescribing medications off-label. For FOD, cannabis falls outside this conventional framework,” the report says. “Recognizing its therapeutic value therefore asks psychiatry to broaden its understanding of what constitutes medicine and evidence-based care, particularly for conditions that lack effective conventional pharmacologic options.” “Five decades of convergent evidence…demonstrate a consistent association between cannabis use and enhanced orgasmic function.” Mulvehill emphasized that incorporating cannabis into sexual medicine “will require openness to recognizing it as a therapeutic ally and developing clinical competence in its responsible use,” while rejecting antiquated framing that’s regarded marijuana as a “gateway” to dangerous drugs that must be “avoided at all costs.” “This stigma shaped society as a whole, as well as the training of psychiatrists and therapists,” Mulvehill, founder of the Female Orgasm Training Institute, said. “Yet cannabis today should be reframed: not as a gateway to illicit drug use, but as a gateway to women’s orgasm—and, more broadly, to restoring women’s sexual agency.” “Female Orgasmic Disorder/Difficulty remains one of the most prevalent yet least adequately treated conditions in women’s health,” the paper says. “The absence of FDA-approved pharmacological treatments, combined with the limited effectiveness of existing psychological and behavioral interventions, reflects a fundamental mismatch between the complexity of orgasmic difficulty and the scope of most current treatment models. The evidence reviewed demonstrates that cannabis occupies a uniquely promising position within this gap.” The analysis points to five decades of research into cannabis that’s demonstrated “consistent associations with improvements in orgasm frequency, ease, and satisfaction, while simultaneously reducing anxiety, inhibition, cognitive distraction, and bodily disconnection, which are core barriers to orgasmic function.” “Integrating cannabis into sexual medicine represents both a clinical and cultural shift,” the author wrote. “What distinguishes cannabis is not merely its ability to improve a single symptom, but its capacity to therapeutically influence multiple orgasm-facilitating and orgasm-inhibiting processes simultaneously, aligning with the multidimensional nature of Female Orgasmic Disorder/Difficulty.” “Moving forward will require an expansion of clinical perspective beyond traditional treatment frameworks, alongside interdisciplinary collaboration, provider education, and clear clinical guidance on dosing and administration to ensure safe, evidence-based care. Together, these developments position cannabis as a legitimate therapeutic ally in advancing equity, effectiveness, and innovation in women’s health care.” A previous scientific review Mulvehill coauthored last year pointed to ample evidence that cannabis is associated with improvements in symptoms of FOD. The research involved an analysis of one randomized controlled trial and 15 observational studies, using data from a total of 8,849 women. Based on the findings, study authors determined that marijuana “appears to be a promising treatment option for FOD/difficulty, with the majority of studies reviewed reporting improvements in orgasm function and satisfaction among women who use cannabis.” Relatedly, another study published last year determined that marijuana use is linked to increased sexual desire and arousal, as well as lower levels of sexual distress. In 2024, a study found that cannabis-infused vaginal suppositories seemed to reduce sexual pain in women after treatment for gynecological cancer. Combining the suppositories with online exercises in “mindful compassion” offered patients even more substantial benefits. “The outcomes favoured the [combined] group,” that research said “in which sexual function, levels of sexual arousal, lubrication, and orgasm increased, and the levels of sexual pain decreased.” Earlier research also found that administration of a broad-spectrum, high-CBD vaginal suppository was associated with “significantly reduced frequency and severity of menstrual-related symptoms” as well as the symptoms’ negative impacts on daily life. As for sexual fulfillment, a separate study last year found that while alcohol might be effective to “facilitate” sex, marijuana is better at enhancing sexual sensitivity and satisfaction. While alcohol increased some elements of sexual attraction—including making people feel more attractive, more extroverted and more desirous—people who used marijuana “have more sensitivity and they are more sexually satisfied than when they consume alcohol,” authors wrote. A broad scientific review of academic research on cannabis and human sexuality published in 2024 concluded that while the relationship between marijuana and sex is a complicated one, use of cannabis is generally associated with more frequent sexual activity as well as increased sexual desire and enjoyment. That article, published in the journal Psychopharmacology, also suggested that lower doses of marijuana may actually be best suited for sexual satisfaction, while higher doses could in fact lead to decreases in desire and performance. And it suggested effects may differ between men and women. Some advocates have cited the potential for cannabis to improve sexual function in women as a reason to add conditions such as FOD as a qualifying condition for medical marijuana. A 2020 study in the journal Sexual Medicine, meanwhile, found that women who used cannabis more often had better sex. Numerous online surveys have also reported positive associations between marijuana and sex. One study even found a connection between the passage of marijuana laws and increased sexual activity. Yet another study, however, cautions that more marijuana doesn’t necessarily mean better sex. A literature review published in 2019 found that cannabis’s impact on libido may depend on dosage, with lower amounts of THC correlating with the highest levels of arousal and satisfaction. Most studies showed that marijuana has a positive effect on women’s sexual function, the study found, but too much THC can actually backfire. Separately, a paper last year in the journal Nature Scientific Reports that purported to be the first scientific study to formally explore the effects of psychedelics on sexual functioning found that drugs such as psilocybin mushrooms and LSD could have beneficial effects on sexual functioning—even months after use. “On the surface, this type of research may seem ‘quirky,’” one of the authors of that study said, “but the psychological aspects of sexual function—including how we think about our own bodies, our attraction to our partners, and our ability to connect to people intimately—are all important to psychological wellbeing in sexually active adults.” Photo courtesy of Max Jackson. The post Marijuana May Be A ‘Gateway To Women’s Orgasm’ In Sexual Health Treatment, Scientific Analysis Finds appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana worker mortgage amendment; AZ cannabis smoke bill passes; CO medical marijuana in hospitals; Study: Psilocybin for quitting cigarettes Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. Jeff Merkley (D-OR) filed an amendment to a housing bill on the Senate floor that would help marijuana industry workers qualify for federally backed mortgage loans by treating cannabis income the same as that derived from other industries. The Florida Supreme Court rejected a marijuana campaign’s request to review state officials’ rejection of tens of thousands of signatures for its legalization initiative, effectively killing the effort to get it on the 2026 ballot. Colorado lawmakers sent Gov. Jared Polis (D) a bill to allow terminally ill patients to use medical cannabis in healthcare facilities such as hospitals—but advocates say recent changes undermine the reform’s intent. The Arizona Senate passed a bill to punish people for creating “excessive” marijuana smoke or odor—including by making it punishable by up to four months in jail if it is “intentional or the person knowingly and substantially interferes with the comfortable enjoyment of life or property.” The Hawaii Senate passed a bill to create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. A new study published by the American Medical Association found that “a single psilocybin dose combined with manualized [cognitive behavioral therapy] yielded significantly greater smoking abstinence than the nicotine patch paired with the same CBT.” “Psilocybin is a promising candidate for smoking cessation that should move forward in the FDA process toward potential approval.” The National Cannabis Industry Association’s Adam Rosenberg and Dentons’s and Eric Berlin describe in a new op-ed how marijuana and hemp industry and advocacy groups have been meeting in an informal group called “The Commission” and are aligned on a “shared vision of more effective federal policy.” Ohio officials are facing a Friday deadline to respond to a lawsuit filed by breweries challenging Gov. Mike DeWine’s (R) veto of portions of a bill that would have allowed sales of hemp THC beverages until the end of the year. / FEDERAL The Drug Enforcement Administration Museum sent a newsletter highlighting the work of the agency’s Foreign-Deployed Advisory Support Team. / STATES Minnesota Gov. Tim Walz (D) signed a cannabis compact with the Lower Sioux Indian Community. Kansas Democratic gubernatorial candidate Cindy Holscher, currently a state senator, discussed her support for legalizing marijuana. The West Virginia House Health and Human Resources Committee advanced a bill to allow prescription of crystalline polymorph psilocybin following federal approval. The Rhode Island House Corporations Committee will consider several bills to amend cannabis laws on Thursday. Tennessee lawmakers discussed the benefits of legalizing marijuana. California regulators are asking a federal court to uphold the state’s cannabis business labor peace requirements. New York regulators took action against an unlicensed marijuana business. Massachusetts marijuana regulators submitted a budget request to lawmakers. Washington State regulators will host feedback sessions about cannabis rules this month. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL UK Prime Minister Keir Starmer responded to a lawmaker’s question about the cost of medical cannabis. / SCIENCE & HEALTH A review concluded that “cannabinoids represent a promising yet underexplored therapeutic option in rare and complex disorders.” A study found that patients “showed significant improvements in [post-treatment Lyme disease] symptom burden and quality of life from study enrollment through 1-month following the second dose of psilocybin (primary endpoint), with significant benefits sustained through 6 months.” / ADVOCACY, OPINION & ANALYSIS The Cannabis Financial Industry Group published a guide on how changes to federal hemp laws affect financial services providers. / BUSINESS Verano Holdings LLC is being sued for allegedly violating privacy laws by printing customers’ names and birthdays on receipts. SHF Holdings, Inc., d/b/a Safe Harbor Financial touted its moves to eliminate debt. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Florida cannabis legalization measure blocked from 2026 ballot (Newsletter: March 11, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This page is helpful for people searching for Escort Sector 43 online. The information about Sector 43 Escort Service is written in a professional way. The guide about Escorts Service in Sector 43 makes the process easy for new users.

Yes, I am entirely agreed with this article, and I just want say that this article is very helpful and enlightening. I also have some precious piece of concerned info !!!!!!Thanks. 해외선물 솔루션

The Hawaii Senate has approved a bill that would create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. After advancing through the committee process, the full Senate on Friday passed the legislation from Sen. Chris Lee (D) in a unanimous vote of 24-0, sending it to the House of Representatives for consideration. The measure would create a Mental Health Emerging Therapies Task Force that’d be tasked with spending two years reviewing the current scientific literature, supporting additional clinical research and “developing policy recommendations for safe, ethical, and culturally-informed implementation” of a psychedelics therapy program. “The legislature finds that addressing the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors, is urgent,” the bill, SB 3199, states. “Suicide continues to be a leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.” Noting that the federal Food and Drug Administration (FDA) has already designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which could lend to future rescheduling under the Controlled Substances Act (CSA), the Hawaii legislation says the state “must proactively prepare public health, clinical, and research systems for safe and equitable implementation.” Members of the task force would have to include representatives of the state Department of Health (DOH), the attorney general’s office, the Office of Wellness and Resilience (OWR), the University of Hawaii’s medical school and more. As drafted, DOH would have overseen the task force, but that was amended in committee to make it the responsibility of “an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education.” “Administrative placement of the task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education shall not be construed to transfer, delegate, diminish, expand, or otherwise modify any regulatory, enforcement, licensing, scheduling, or rulemaking authority vested in the Department of Health, Board of Pharmacy, or any other state agency,” the bill as revised says. “All statutory authority relating to controlled substances, professional licensure, and public health regulation shall remain with the appropriate executive branch agencies as provided by law.” It appears that the bill would build upon prior work conducted by a separate psychedelics task force that convened for the first time in 2023, with a similar goal of exploring pathways for therapeutic access into FDA-approved breakthrough drugs like psilocybin. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, Hawaii senators recently approved a bill to legalize low-dose and low-potency marijuana, even as their counterparts in the House of Representatives say cannabis prohibition will not be ended in the state this year. A separate marijuana legalization bill that contained provisions making the reform contingent on changes to federal law or the state Constitution, SB 2421, was deferred for action. Both Senate and House panels additionally deferred action on a measure to allow for the sale of certain hemp-derived cannabinoid products. The Senate committee action comes after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. On Thursday, another Hawaii Senate committee separately passed legislation to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. Image courtesy of CostaPPR. The post Hawaii Senate Passes Bill To Create Psychedelics Task Force And Study Pathways To Access Psilocybin And MDMA appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Arizona Senate has passed a bill to penalize people who create “excessive” amounts of marijuana smoke or odor—a policy that’s received pushback from advocates who say the proposals amount to overreach that wasn’t envisioned under the state’s voter-approved legalization law. After being significantly dialed back in response to that criticism, the bill from Sen. J.D. Mesnard (R) advanced through the full chamber on Monday in a 20-9 vote. It now heads to the state House of Representatives for consideration. A separate companion resolution to put the issue before voters to decide failed, however, in a narrow 14-15 vote. Mesnard later made a successful motion to reconsider that defeat, however, so the measure could end up advancing upon a revote. As introduced, both measures would have added broad criminalization provisions back into the state’s cannabis use laws. But most of that punitive language was revised by the Senate Committee of the Whole. For example, it was changed to provide a clearer definition of “excessive” smoke and remove a reference to making the offense a “crime.” The bill as passed, however, would make it a public nuisance punishable by up to four months in jail and a $750 fine to create “excessive marijuana smoke or odor…if the person’s conduct is intentional or the person knowingly and substantially interferes with the comfortable enjoyment of life or property.” The latest revised definition of excessive cannabis smoke or odor describes it as “airborne emissions resulting from the burning, heating or vaporizing of marijuana or marijuana products,” according to a summary of the adopted amendment. Such emissions must also be “detectable by a reasonable person of ordinary sensibilities on other private property” and “occur for more than 30 consecutive minutes on a single occasion or on three or more separate days within a 30-day period.” The bill (SB 1725) that advanced through the full Senate and resolution (SCR 1048) that failed also now specify that “lawful possession or use of marijuana does not preclude a finding of nuisance, except that a court may consider possession of a valid registry identification card as a mitigating factor,” and they provide that “a person is not liable for committing a private nuisance unless the person has received notice of the interference and fails to abate it within five days.” Under the revised legislation, the affected party would first have to file a compliant with local officials before they pursue action with the state, but only if the municipality has already adopted an ordinance regulating excessive cannabis smoke or odor. A person would be deemed in violation of the law if a local court has issued a written order directing them to “abate excessive marijuana smoke or odor that constitutes a nuance” and that person “knowingly violates or refuses to comply with the order.” Each day of non-compliance after failing to adhere to the order would be consider a separate offense, and failure to comply would be a petty offense. “I wanted to clarify that we eliminated almost all of the criminal aspect of this. The only thing that remains is if you’re doing something intentional and substantial,” Mesnard said on Monday. “I’m not trying to interfere with somebody’s right to smoke. They can get high any number of other ways that this bill doesn’t implicate, but the moment that it does start to impact other people and their families, then it becomes an issue.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In the background of this legislation, anti-cannabis activists are working to put an initiative on the state’s November ballot that would significantly roll back its voter-approved marijuana legalization law. A GOP congressional lawmaker said recently he’d like to see his state take that action—but he also acknowledged that President Donald Trump’s recent federal rescheduling order could complicate that prohibitionist push. Under the proposal, possession would remain lawful if voters chose to enact the initiative—and Arizona’s medical marijuana program would remain intact—but the commercial market for recreational cannabis that’s evolved since voters approved an adult-use legalization measure in 2020 would be quashed. A findings section on the latest initiative states that “the proliferation of marijuana establishments and recreational marijuana sales in this state have produced unintended consequences and negative effects relating to the public health, safety, and welfare of Arizonans, including increased marijuana use among children, environmental concerns, increased demands for water resources, public nuisances, market instability, and illicit market activities.” “Arizona’s legal marijuana sales have declined for two consecutive years, resulting in less tax revenue for this state, while some patients have relied on recreational use of marijuana instead of utilizing the benefits of this state’s medical marijuana program,” it says. The initiative would also instruct the legislature to make conforming changes by amending existing statute as it relates to the commercial industry, including tax and advertising rules. In order to make the ballot, the campaign will need to collect 255,949 valid signatures by July 2. If the proposal goes to voters and is approved, it would take effect in January 2028. It remains to be seen if there will be an appetite for repeal among voters, as 60 percent of the electorate approved legalization at the ballot in 2020. What’s more a poll from last year found majority support for medical cannabis legalization (86 percent), adult-use legalization (69 percent) and banking reform (78 percent). Meanwhile, senior residents in Arizona independent living communities could soon see a different kind of care service available in their neighborhoods: Kiosks allowing them to view and buy marijuana products from licensed dispensaries. The retailer Life Is Chill and cannabis technology company LoveBud announced last week that they were partnering for the launch of the novel initiative, which will involve deploying the kiosks in participating senior living communities that residents can use to learn about and order marijuana products for delivery. Photo courtesy of Martin Alonso. The post Arizona Senate Passes Bill To Punish People Over ‘Excessive’ Marijuana Odor Or Smoke appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Just one dose of psilocybin combined with therapy is associated with “significantly increased long-term abstinence” from cigarettes compared to nicotine patches, according to a new study published by the American Medical Association (AMA) that indicates the psychedelic “holds potential in the treatment of tobacco use disorder.” Researchers at Johns Hopkins University School of Medicine and the University of Alabama at Birmingham conducted the study, published in JAMA Substance Use and Addiction, finding more evidence about the therapeutic potential of single-dose psilocybin in tandem with cognitive behavioral therapy (CBT). The randomized clinical trial of cigarette smokers involved administering one high dose (30mg/70kg) of psilocybin or 8-10 weeks of Food and Drug Administration- (FDA) approved nicotine patch treatment, with both groups participating in a 13-week CBT program for smoking cessation. “A single psilocybin dose combined with manualized CBT yielded significantly greater smoking abstinence than the nicotine patch paired with the same CBT.” “A total of 82 psychiatrically healthy adult smokers participated in the study, with 68 (82.9 percent) completing the 6-month follow-up,” the paper says. “At 6-month follow-up, 17 participants receiving psilocybin (40.5 percent) exhibited biochemically verified prolonged abstinence compared with 4 participants using the nicotine patch (10.0 percent), and 22 participants receiving psilocybin (52.4 percent) exhibited biochemically verified 7-day point prevalence abstinence compared with 10 participants using the nicotine patch (25.0 percent).” Put another way, smokers who received psilocybin had more than six times greater odds of prolonged abstinence and more than three times greater odds of seven-day abstinence compared to the nicotine patch participants. “In this pilot randomized clinical trial, one dose of psilocybin with manualized CBT significantly increased long-term abstinence compared with nicotine patch treatment with CBT,” the authors said. “Psilocybin abstinence rates were higher than typical treatments, suggesting promise for tobacco smoking cessation.” “Participants in the psilocybin group smoked a mean of approximately 50 percent fewer [cigarettes per day] between the target quit date and 6-month follow-up,” they said. “The results of this study add to the increasing evidence that psychedelic treatment may have general anti-addiction efficacy across various addictive drugs.” “Psilocybin’s lack of direct interaction with nicotinic acetylcholine receptors (or receptors mediating the effects of other addictive drugs) highlights psychedelic therapy as a unique approach wherein the pharmacotherapy does not directly alter drug reinforcement or withdrawal but may instead act via higher-order psychological systems, such as changes in self-concept40 and enhanced psychological flexibility. Such mechanisms may also account for transdiagnostic benefits of psychedelic therapies (eg, for depression and anxiety). These psychological changes are likely associated with corresponding biological processes, just as there are presumably biological changes associated with successful psychotherapy. However, these biological processes are probably of a different nature and more difficult to characterize than those of traditional pharmacotherapies.” The study authors also said that the results of the psilocybin-assisted therapy clinical trial makes the psychedelic a “promising candidate for smoking cessation that should move forward in the FDA process toward potential approval.” As psychedelics policy reform advances in state legislatures across the U.S. and in Congress, Americans have shown growing interest in exploring the therapeutic potential of substances like psilocybin. To that point, a RAND Corporation analysis recently found that nearly 10 million American adults microdosed psychedelic drugs such as psilocybin, LSD or MDMA in 2025. A scientific review published by AMA last year that use of psilocybin has “surged” in the U.S. in recent years amid the decriminalization movement and in light of “promising clinical trial results” on its therapeutic potential. But the paper also pointed out that current federal laws present “a major barrier” to researchers gaining a better understanding of the psychedelic substance’s true impacts. Meanwhile, another study from last year found that psilocybin-assisted psychotherapy “showed significant reductions in alcohol consumption and high smoking cessation rates” and has potential to lessen opioid dependence. In 2024, meanwhile, two other studies—including one with contributions from a top federal drug official—examined psychedelics and alcohol use disorder (AUD). One found that a single dose of psilocybin “was safe and effective in reducing alcohol consumption in AUD patients,” while the other concludes that classic psychedelics like psilocybin and LSD “have demonstrated potential for treating drug addiction, especially AUD.” The National Institutes of Health that year also announced that it would put $2.4 million toward funding studies on the use of psychedelics to treat methamphetamine use disorders—funding that came as federal health officials noted sharp increases in deaths from methamphetamine and other psychostimulants in recent years, with fatal overdoses involving the substances rising nearly fivefold between 2015 and 2022. In 2023, the National Institute on Drug Abuse (NIDA) announced a $1.5 million funding round to further study psychedelics and addiction. Other research has also suggested that psychedelics could unlock promising new pathways to treat addiction. A first-of-its-kind analysis in 2023 offered novel insights into exactly how psychedelic-assisted therapy works for people with alcohol use disorder. In 2024, the National Center for Complementary and Integrative Health (NCCIH), which is part of the National Institutes of Health (NIH), identified the treatment of alcohol use disorder as one of a number of possible benefits of psilocybin, despite the substance remaining a Schedule I controlled substance under U.S. law. The agency highlighted a 2022 study that “suggested that psilocybin may be helpful for alcohol use disorder.” The research found people who were in psilocybin-assisted therapy had fewer heavy-drinking days over 32 weeks than the control group, which NCCIH said “suggests that psilocybin may be helpful for alcohol use disorder.” The post Psilocybin Helps People Quit Cigarettes More Effectively Than Nicotine Patches Do, American Medical Association-Published Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Colorado House of Representatives has sent a bill to the governor that would allow terminally ill patients to use medical marijuana in healthcare facilities such as hospitals—with recently added provisions that advocates argue undermine the measure’s original intent. Weeks after advancing through the Senate, with amendments, the legislation from Sen. Kyle Mullica (D) cleared the full House on third reading in a 49-12 vote on Tuesday. It now heads to the desk of Gov. Jared Polis (D), who has long championed cannabis reform in the state. “This is a good bill,” Rep. Ryan Gonzalez (R) said on the floor. “I think we should be able to give patients who are terminally ill, and other conditions, an option to have alternative methods of treatment. And that includes cannabis.” “I just can’t stress enough the importance of this bill for my district, for my community and for the people that I represent,” he said. “I went back to my district, and they were very excited about this—for people who have an opportunity to do this.” That said, advocates have been critical about changes made throughout the legislative process, arguing, for example, that making it so hospitals would have the option—rather than a mandate—to allow medical cannabis use in their facilities fundamentally undermines the intent of the reform. Jim Bartell, the father of a young California patient who passed away and who inspired the policy that’s become known as Ryan’s Law in his home state and several others, urged members of a House committee earlier this month to go back to original language of the bill and “use the original language of ‘shall’ and ‘must’” so that it doesn’t create a patchwork network of health facilities that permit or prohibit medical cannabis use. “For families like mine, this legislation is not theoretical. It’s part of ethical and compassionate care,” he said. Lieder, one of the bill sponsors, said in response to committee testimony that she had just learned about the amendments that advocates are opposing. That point was echoed during second reading on the House floor on Monday, but the measure was not ultimately revised accordingly. Under SB 26-007, health facilities would be permitted to develop guidelines for the use, storage and administration of medical marijuana. The Colorado Department of Public Health and Environment (CDPHE) would be prohibited from requiring compliance with the policy as a condition of obtaining or renewing a license or certification under the bill. Health facilities would be allowed to suspend the policy change if they risked enforcement action by a federal agency. “In FY 2026-27, workload in the Health Facilities and Emergency Medical Services Division in CDPHE will minimally increase to conduct outreach and education to licensed health care facilities regarding medical marijuana use,” a fiscal impact analysis says. “The department may also require legal services, provided by the Department of Law, related to rulemaking and implementation. This workload can be accomplished within existing appropriations.” Other amendments adopted in the Senate add additional compliance language, clarify that health facilities wouldn’t be required to store or dispense medical cannabis and limit legal liability for health institutions that permit medical marijuana use. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Colorado, the state saw over $1 billion in marijuana sales—a milestone the governor touted in December. The governor also said last month that his state should not have joined a lawsuit supporting the federal ban on gun ownership by people who use marijuana that recently went before the U.S. Supreme Court—and he personally opposes the state attorney general’s “legal position on this.” Photo courtesy of Mike Latimer. The post Colorado Bill To Allow Medical Marijuana Use In Hospitals Heads To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Florida’s Supreme Court has shut down a marijuana campaign’s appeal that sought judicial intervention to restore tens of thousands of signatures that the state invalidated for a legalization ballot initiative. After Smart & Safe Florida submitted the appeal last month, the court on Monday said it was declining to review the petition over 71,000 invalidated signatures and that “no motion for rehearing will be entertained.” The latest ruling comes after the court agreed to close a separate case involving a legal review into the ballot measure. The state’s First District Court of Appeal submitted a notice to invoke discretionary jurisdiction and notice of appeal to the Florida Supreme Court last month, opening back up the possibility that voters could decide on legalization at the polls later this year. But that was contingent on justices accepting the case and the campaign prevailing, which did not come to fruition. “This cause having heretofore been submitted to the Court on jurisdictional briefs and portions of the record deemed necessary to reflect jurisdiction under Article V, Section 3(b), Florida Constitution, and the Court having determined that it should decline to accept jurisdiction, it is ordered that the petition for review is denied,” the court said on Monday. Marijuana Moment reached out to the cannabis campaign for comment, but a representative was not immediately available. New material in Smart & Safe Florida v. Secretary, Florida Department of State, et al. (petition for review denied). See the docket https://t.co/RzQBcUIN5K pic.twitter.com/pxpzrBVdky — FloridaSupremeCourt (@flcourts) March 9, 2026 Back in December, advocates filed a lawsuit in the Leon County circuit court, claiming Secretary of State Cord Byrd (R) unlawfully directed county election officials to invalidate about 42,000 signatures from so-called “inactive” voters and roughly 29,000 signatures collected by out-of-state petitioners. That lawsuit came after another court upheld a previous decision to strike about 200,000 signatures that the state said were invalid because the petitions didn’t include the full text of the proposed initiative. The campaign contested the legal interpretation, but it declined to appeal the decision based on their confidence they’d collected enough signatures to make up the difference. Smart & Safe Florida has generally disputed the secretary of state’s signature count, asserting the campaign submitted over 1.4 million petitions—hundreds of thousands more than the 880,062 valid signatures required to go before voters. In a recent filing with the Supreme Court, Attorney General James Uthmeier (R) said his office was withdrawing its earlier request for a legal review in the constitutionality of the proposed cannabis initiative because the state claimed the campaign submitted an insufficient number of signed petitions. The last count, according to the secretary of state’s office, was 783,592 validated signatures. In its reply brief, Smart & Safe Florida said the secretary of state’s office made a determination that the campaign didn’t satisfy requirements for ballot placement based on a “conclusion that the Sponsor failed to meet the requisite signature threshold in light of the invalidations that the Sponsor is contesting.” Ahead of the signature turn-in, Florida’s attorney general and several business and anti-marijuana groups urged the state Supreme Court to block the cannabis initiative, calling it “fatally flawed” and unconstitutional. The Florida Chamber of Commerce, Florida Legal Foundation and Judge Frank Shepherd filed a separate joint brief stating that the parties remain “especially vigilant about the abuse of the citizen initiative process by out-of-state interests that think of Florida as just another market and the citizen initiative process as just another means of exploiting that market.” The Florida Chamber of Commerce has consistently opposed attempts to move forward with adult-use legalization, even as its own polling has shown majority support for the reform. The campaign fought several legal battles this cycle to ensure that its initiative is able to qualify for ballot placement. In January, the state attorney general’s office opened dozens of criminal investigations and submitted subpoenas requesting records from Smart & Safe Florida and its contractors and subcontractors over alleged fraud related to the petitioning effort. Activists said in November that they’d collected more than one million signatures to put the cannabis measure on the ballot, but it’s also challenged officials at the state Supreme Court level over delays the certification process, arguing that the review of the ballot content and summary should have moving forward months ago when it reached an initial signature threshold. The state then agreed to move forward with the processing. Meanwhile, the cannabis campaign recently faced another complication as it continued to litigate the status of its 2026 signature drive. Under a new election law, the hundreds of thousands of signatures activists already collected for this year will not be carried over into the 2028 cycle. Gov. Ron DeSantis (R) campaigned heavily against an earlier version of the legalization proposal, which received a majority of voters in 2024 but not enough to meet the 60 percent threshold required to pass a constitutional amendment. Former Attorney General Ashley Moody (R) unsuccessfully contested the prior initiative in the courts. Last March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to DeSantis. The money was used to fight against a citizen ballot initiative, vehemently opposed by the governor, that would have legalized marijuana for adults. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said last year that the newest marijuana legalization measure was in “big time trouble” with the state Supreme Court, predicting it would be blocked from going before voters this year. “There’s a lot of different perspectives on on marijuana,” DeSantis said. “It should not be in our Constitution. If you feel strongly about it, you have elections for the legislature. Go back candidates that you believe will be able to deliver what your vision is on that.” “But when you put these things in the Constitution—and I think, I mean, the way they wrote, there’s all kinds of things going on in here. I think it’s going to have big time trouble getting through the Florida Supreme Court,” he said. The latest initiative was filed with the secretary of state’s office just months after the initial version failed during the November 2024 election—despite an endorsement from President Donald Trump. Smart & Safe Florida expressed optimism that the revised version would succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” In 2023, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released last February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last week, the Florida House of Representatives passed a bill to significantly reduce the fee for military veterans to obtain medical marijuana registry identification cards. Here’s an overview of other pending Florida marijuana bills: A House lawmaker is sponsoring a bill to legalize recreational marijuana that also aims to break up what he calls “monopolies” in the state’s current medical cannabis program by revising the business licensing structure. Another representative’s bill would protect the parental rights of medical cannabis patients, preventing them from losing custody of their children for using their medicine in accordance with state law. Other legislation would also allow doctors to recommend cannabis to any patient who has a condition for which they have been prescribed opioids. A senator is sponsoring a bill to legalize home cultivation of marijuana for registered medical cannabis patients in the state. Photo elements courtesy of rawpixel and Philip Steffan. The post Florida Supreme Court Rejects Marijuana Campaign’s Appeal To Restore Legalization Ballot Signatures, Effectively Ending 2026 Push appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“In addition to potential criminal penalties, the veto will force them, collectively, to lay off dozens of employees and will cost them millions of dollars in investments and lost sales.” By David Beasley, The Center Square The state of Ohio has until Friday to respond to a lawsuit by breweries challenging Gov. Mike DeWine’s (R) veto of portions of a bill that would have allowed beer companies to continue selling hemp beverages until the end of the year. Last Friday, a group of brewers sued the state, challenging DeWine’s “line item” veto of portions of Senate Bill 56 that would have given companies until December 31 to transition out of the hemp beverage business and sell their inventories in response to new federal legislation on hemp products. Even though Ohio voters in 2023 approved a measure legalizing the recreational use of marijuana, SB56, passed late last year, placed new restrictions on the use and sale of hemp products. SB56 is set to take effect March 20, according to the emergency motion filed before the state Supreme Court on Friday. Beer companies face “potential criminal enforcement actions against them for possessing millions of dollars’ worth of inventory that they purchased in good faith before the governor’s veto,” the lawsuit states. “In addition to potential criminal penalties, the veto will force them, collectively, to lay off dozens of employees and will cost them millions of dollars in investments and lost sales.” On Monday, the state Supreme Court gave the state until 3 p.m. this Friday to respond to the emergency motion. “No requests or stipulations for extension of time shall be filed,” the court said. According to the beer companies’ emergency motion, DeWine overstepped his line-item veto authority by deleting an entire section of SB56. The motion quotes one of the delegates to Ohio’s Constitutional Convention of 1912 when arguing for for the current language limiting the governor to vetoing only items not sections, ‘“You can take the life out of any bill by cutting a section out of it.’” In making the line item veto, DeWine “thought he knew better than the people of Ohio,” the brewers said. DeWine spokesman Dan Tierney disagrees. “No Ohio voter ever approved THC beverages to be sold at restaurants or breweries,” he told The Center Square. This story was first published by The Center Square. The post Ohio Officials Face Friday Deadline To Respond To Hemp THC Drink Lawsuit appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“With marijuana and hemp leaders working together toward a shared vision of more effective federal policy, the path ahead is brighter for the entire cannabinoid marketplace.” By Adam Rosenberg, National Cannabis Industry Association and Eric Berlin, Dentons Last fall, we wrote that marijuana and hemp businesses were working together as a group informally called the “Commission” to find areas of substantial agreement and that collaboration was going better than expected. Today, we share the first results of those discussions. The effort has brought together leaders from many of the most prominent marijuana and hemp industry and advocacy groups in the United States, representing thousands of businesses across marijuana, intoxicating hemp, non-intoxicating hemp and cannabinoid innovation. The conversation continues to mature as policymakers at both the state and federal levels confront the urgent question of how to build a regulatory framework that reflects the realities of today’s cannabinoid marketplace and avoids the confusion created by arbitrary legal divisions. One of the quiet casualties of cannabis reform has been how THC itself is regulated. Current law artificially distinguishes “hemp” and “marijuana” based on factors like plant genetics and THC concentration of the source material, creating two different legal universes for a singular plant species, Cannabis sativa L. This bifurcation generates confusion and even latent hostility within the cannabis community. Consumers are expected to navigate a maze of labels with phrases like hemp-derived, Farm Bill compliant, delta-8, delta-9, medical and recreational. However, there is no clear guidance on the products’ effects and impacts on public health and safety. Companies selling products with similar effects often become territorial about the regulatory scheme, or lack thereof, under which they operate. The Commission’s discussions have yielded ten statements reflecting emerging consensus among participants, representing a shift that moves the debate away from competing market identities and toward consumer-centered standards. The statements offer a pragmatic blueprint grounded in product safety, regulatory clarity and respect for state authority. They are as follows: Regulating End Product vs. Source Material Formulation, form factor, intoxicating potential and intended use, instead of just the source material (hemp vs marijuana), should determine how cannabinoid products are regulated. Hemp for fiber, hurd and grain should be regulated separately from cannabinoid production. Age Restrictions The sale of any ingestible product with a quantifiable amount of THC should be restricted to adults 21+ or in compliance with a state medical marijuana program. Synthetic Cannabinoids Compounds that are not naturally found in the cannabis plant should not be marketed or regulated as cannabis products (and can be addressed outside of cannabis policy). Distinguishing Distribution Channels Consistent standards for labeling, testing, quality control and product safety should be uniform across states. Federal agency oversight should be split between the Alcohol and Tobacco Tax and Trade Bureau, the Food and Drug Administration and the United States Department of Agriculture based on intended use and intoxicating potential. States should have authority over availability of products and how they are distributed to consumers. Interstate Commerce Interstate commerce of wholesale cannabis products should be permitted, with a reasonable transition period for products that are currently restricted to intrastate commerce. Traceability and product authentication standards should be established uniformly across the country. Licensing States should retain their traditional role of determining the license structure (if any) within their state, subject to Dormant Commerce Clause concerns. What began as good-faith dialogue has now produced shared principles for regulating cannabinoid products. This emerging consensus honors the plant’s diversity and the current market’s realities rather than illusory categories. With marijuana and hemp leaders working together toward a shared vision of more effective federal policy, the path ahead is brighter for the entire cannabinoid marketplace. Adam Rosenberg is Chairman of the Board of the National Cannabis Industry Association (NCIA) and Partner at Vlasic Bioscience, with extensive experience spanning the entire cannabinoid supply chain, investment, education, and regulatory policy. Eric Berlin is a partner at Dentons and leads the firm’s U.S. Cannabis practice, advising clients on regulatory, transactional, and policy matters across the cannabinoid marketplace. The post Marijuana And Hemp Leaders Have Found Agreement On Many Significant Policy Issues (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Fantastic submit, Many thanks regarding revealing This kind of information. Fantasticly composed write-up, only if almost all people supplied the identical amount of articles when you, the net would have been a greater spot. You should keep writing! สล็อตวอเลท

A Democratic senator is seeking to amend a House-passed housing bill with provisions that would allow people who work in the state-legal marijuana industry to qualify for federal mortgage loans. As the Senate prepares to take up the Housing for the 21st Century Act—which cleared the House last month with rare, overwhelming bipartisan support—Sen. Jeff Merkley (D-OR) submitted an amendment to extend home loan eligibility for those working at licensed cannabis businesses. Specifically, the proposed amendment stipulates that income derived from state-sanctioned marijuana businesses would be treated no differently than that from other industries for the purposes of obtaining federally backed single-family mortgage loans, with additional protections against forfeiture based on participation in the cannabis market. Federally backed loans would include any that are “secured by a first or subordinate lien on residential real property, including individual units of condominiums and cooperatives, designed principally for the occupancy of 1 to 4 families” and insured by the National Housing Act, U.S. Department of Veterans Affairs (VA), U.S. Department of Agriculture (USDA) or “purchased or securitized by the Federal Home Loan Mortgage Corporation or the Federal National Mortgage Association.” “Income derived from a State-sanctioned marijuana business that operates within a State, an Indian Tribe, or a political subdivision of a State that allows the cultivation, production, manufacture, sale, transportation, display, dispensing, distribution, or purchase of marijuana pursuant to a law or regulation of the State, Indian Tribe, or political subdivision, as applicable, or a service provider (wherever located), shall be considered in the same manner as any other legal income for purposes of determining eligibility for a federally backed mortgage loan for a 1- to 4-unit property that is the principal residence of the mortgagor.” The amendment would also secure protections against legal liability for a loan servicer for “providing, insuring, guaranteeing, purchasing, or securitizing a mortgage to an otherwise qualified borrower on the basis of the income” derived from state-legal marijuana businesses. The law would take effect within 180 days of the underlying bill’s enactment. Whether the amendment is considered on the floor and adopted by the Senate remains to be seen, but any changes to the housing legislation would send it back to the House for consideration before it potentially heads to the desk of President Donald Trump. Mortgage loan eligibility provisions were discussed as amendments to a bipartisan marijuana banking bill last session, with language similar to Merkley’s proposal making it into a negotiated version of the Secure and Fair Enforcement Regulation (SAFER) Banking Act in 2023. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — While that legislation has long been considered one of the more practical, incremental reforms that could make it through Congress and onto the president’s desk, the bill hasn’t been refiled for the current session as advocates and stakeholders await action on a pending federal marijuana rescheduling directive. There are some lawmakers who’ve expressed optimism that the banking legislation could be revived if marijuana is ultimately moved from Scheduled I to Schedule III of the Controlled Substances Act (CSA), though that modest reclassification would not on its own free up all financial services for the sector. It would, however, allow cannabis operators to take federal tax deductions they’ve been barred from under Internal Revenue Services code 280E. The post Senate Amendment Would Let Marijuana Industry Workers Qualify For Federal Mortgage Loans appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Excellent roundup — I appreciated the filter for low-population but active servers. Smaller communities often offer friendlier vibes and cooperation. Real player rankings showed which small servers thrive. 해외선물 분양

OK gov slams medical marijuana; VA cannabis user parental rights; TN momentum from rescheduling; TX hemp rules; Study: CBD as medication substitute Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Rep. Byron Donalds (R-FL), who is running for Florida governor, admitted to selling marijuana as a young man—even though he opposed a ballot measure to legalize cannabis in his state in 2024 and worked to block sentencing reform in Washington, D.C. Oklahoma Gov. Kevin Stitt (R) said he thinks legislative leaders will support his plan to roll back medical cannabis legalization by putting the issue on the ballot again—even though the Senate president and House speaker have publicly pushed back against the idea. Virginia lawmakers sent Gov. Abigail Spanberger (D) a bill to protect the parental rights of marijuana consumers by making it so a “person’s legal possession or consumption of substances…alone shall not serve as a basis to restrict custody or visitation.” Tennessee’s House majority leader said federal marijuana rescheduling as ordered by President Donald Trump would resolve his “biggest objection” to legalizing medical cannabis at the state level. The Minnesota House Health Finance and Policy Committee approved a bill to legalize the regulated therapeutic use of psilocybin for adults 21 and older, while rescheduling the psychedelic under state statute. The Texas Department of State Health Services adopted changes to hemp rules that include a strict total THC standard that advocates say will wipe out much of the legal industry but also have lower licensing fees for businesses than were previously proposed. A new federally funded study found that “CBD use as a substitute or adjunct to medications was common among US adults particularly for pain medications.” “Millions of US adults use CBD as a substitute and adjunct for a wide range of health conditions.” Sen. Pete Ricketts (R-NE) dodged a question about why Nebraska was left out of a congressionally approved rider protecting state medical cannabis laws from federal interference and whether he would support adding it in. / FEDERAL President Donald Trump announced the formation of an international Americas Counter Cartel Coalition. Alabama Democratic Senate candidate Lamont Lavender discussed his support for legalizing marijuana. / STATES Pennsylvania Gov. Josh Shapiro (D) tweeted, “Let’s be real: Pennsylvanians who want to buy recreational marijuana are just driving across the border to one of the 5 neighboring states who have already legalized it. Legalizing adult-use marijuana could generate $1.3 BILLION in new revenue over the first five years. This is big business — and right now, we’re losing that revenue to our neighbors.” California’s treasurer appeared on a cannabis podcast. The Colorado House Business Affairs & Labor Committee approved a bill to create a licensing system for cannabis events. The Georgia House Judiciary Non-Civil Committee rejected bills to legalize marijuana, facilitate pardons for prior convictions and remove the ability of police to conduct searches based on the smell of cannabis alone. Maryland lawmakers are pushing for funding for a nonprofit focused on cannabis industry education, workforce development and community engagement. Ohio officials are being sued over an impending ban on hemp THC products. Missouri regulators issued a variance allowing use of humidity control packets in final marijuana products. Massachusetts regulators published guidance about municipal opt-in procedures for marijuana social consumption businesses. Montana regulators sent updates about various cannabis issues. Washington State regulators will consider changes to rules on medical cannabis tax exemption on Tuesday. Michigan regulators will host a marijuana summit for municipalities on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Jamaica’s minister of industry, investment and commerce announced new rules that will allow community groups to cultivate up to 10 acres of medical cannabis. Canadian officials sent a reminder about rules for cannabis facility tours. / SCIENCE & HEALTH A study of mice suggested that “CBD can have beneficial effects on some of the pathology associated with [Alzheimer’s disease], even in an aggressive model of this neurodegenerative disease, but the impacts on impaired behavior were minimal.” A study found that “delayed psilocybin treatment after repeated mild traumatic brain injury recovers chronic behavioural deficits, reduces microglial density, and enhances hippocampal neurogenesis in rats.” / BUSINESS Tilray Brands, Inc. completed its acquisition of BrewDog Brewing Australia Pty Ltd. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post GOP congressman’s cannabis sales arrest (Newsletter: March 10, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

You actually get to play interior designer, choosing Papa's Games furniture that affects how much customers tip or how long they’re willing to wait.

It's which means that amazing together with inspiring. We really enjoy any designs together with whoever should get it all during the post shall be grinning. 해외선물 분양

Minnesota lawmakers have approved a bill that would legalize the regulated therapeutic use of psilocybin for adults 21 and older, while rescheduling the psychedelic under state statute. Members of the House Health Finance and Policy Committee on Monday passed the legislation from Rep. Andy Smith (DFL) in a voice vote. The proposal next heads to the Commerce Finance and Policy Committee. Smith also sponsored a similar measure last year that did not ultimately advance to enactment. Under the current bill, which was revised with a substitute amendment at the committee hearing, qualified patients 21 and older could receive psilocybin-assisted therapy in an “approved private residence or at a licensed treatment facility,” according to a summary from the Minnesota House Research Department. “No one in this committee, I know, questions the fact that mental illness is one of the defining issues in our society today,” Smith, who described the legislation as responsive to recommendations from a state psychedelics task force that was formed under a separate law, said. “Today in this committee, we are talking about a new tool: A therapeutic psilocybin program here in Minnesota that has great potential.” “It will help Minnesotans who are struggling with a wide variety of mental illnesses from substance use disorder, depression, PTSD, anxiety, chronic pain and more,” he said, before describing the key provisions of the proposed legislation. A registered facilitator would need to administer the psychedelic. To start, the program would need to involve licensing 20 to 50 facilitators, with at least three approved testing facilities for psilocybin. No more than 1,000 patients could participate in the psychedelic therapy for the first three years of the law’s implementation. The Department of Health (DOH) and Office of Cannabis Management (OCM) would be responsible for overseeing the program and establishing rules, with the heath commissioner also tasked with collaborating with a newly established Psychedelic Medicine Advisory Committee on the initiative. Psilocybin sessions would involve “preparation” with a patient-facilitator consultation, “administration” where patients would receive the psychedelic and “integration” where patients would work with professionals to process the therapeutic experience. Further, HF 2906 as amended incorporates protections for health professionals that help facilitate the program. And it would impose penalties for violations of the law such as the unsanctioned administration or cultivation of psilocybin outside of the parameters of the program. “I think a lot of the when somebody hears about this initially and thinks, ‘Hey, medicinal cannabis program’—a lot of criticism that is ‘Oh, it’s the nose under the camel’s tent for legalization’ or whatnot,” Rep. Nolan West (R), who is cosponsoring the legislation, said. “This is a pilot program.” The lawmaker also pointed out that interest in the therapeutic potential of psychedelics extends not just across party lines but all the way up to the White House, where U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. and other administration officials have discussed expanding access to the novel therapies. In addition to creating the psilocybin therapy program, the Minnesota bill calls for the psychedelic to be moved from Schedule I to Schedule IV of the state’s controlled substances list, reflecting a low abuse potential and low risk of dependency. One of the open questions for the reform is how to ensure it will receive adequate funding, and so while the sponsor said he isn’t expecting significant political resistance to the underlying purpose of the legislation, it’s possible spending concerns could prove problematic. “If it doesn’t happen this year, I feel very confident in the next budget year that we’ll be able to get this done,” Smith told The Minnesota Star Tribune. Kurtis Hanna, board president for the Psychedelic Access Project, told Marijuana Moment that the advancement of the bill through committee with a bipartisan vote is “encouraging” when “the Minnesota legislature is as divided as ever.” “Veterans, mental health practitioners, doctors and patients came out in full force today to support providing another tool in the toolbox to Minnesotans suffering from mental health issues,” he said. “I’m excited to see this issue gain more traction as it moves through the next few committee stops on its way to a full vote in the House and Senate.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Minnesota, the state’s first government-run marijuana retailer recently opened its doors, marking another milestone in the state’s adult-use cannabis program. Last September, Minnesota officials granted the state’s first-ever marijuana event organizer license, allowing adults to buy and consume cannabis products on-site at a festival. The first non-tribal marijuana shops opened for sales to adults 21 and older earlier that month. Also last year, the Minnesota city of Eden Prairie sought suggestions from residents on what to name a new, government-branded cannabis gummy product to be sold at municipal liquor stores. Minnesota’s House of Representatives circulated a poll at last year’s State Fair that asked attendees about the idea of allowing localities to enact bans on marijuana businesses within their borders. Most respondents who have an opinion on the issue agree with the policy, despite it not currently being a part of the state’s cannabis laws. Ahead of the enactment of legalization in Minnesota, lawmakers’ separate State Fair polls found majority support for the reform. The governor has also selected a top cannabis regulator for the state who will oversee the adult-use market rollout. Last June, June, OCM issued the state’s first recreational marijuana license for a cultivation microbusiness. OCM said at the time that it’s taking further steps to build up in the industry and create opportunities to entrepreneurs, including opening a new licensing window for cannabis testing facilities, accepting the first applications for marijuana event licenses and verifying more social equity status requests. Separately, after Minnesota lawmakers passed a bill to end the criminalization of bong water containing trace amount of drugs, the governor signed the measure into law last May. The change addresses an existing policy that had allowed law enforcement to treat quantities of bong water greater than four ounces as equivalent to the pure, uncut version of whatever drug the device was used to consume. Meanwhile, Minnesota Gov. Tim Walz (D) said in December that the state is “exploring” how to respond to an impending federal ban on hemp THC products, which would be “very disruptive” to a “thriving industry.” Image courtesy of CostaPPR. The post Minnesota Lawmakers Approve Bill To Legalize Psilocybin Therapy And Reschedule The Psychedelic Under State Law appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Texas officials have adopted a series of new rules for the state’s hemp market—with certain revisions that advocates and stakeholders call a “direct victory,” including changes to make participation in the industry more affordable, and other regulations that threaten to severely restrict product availability. The Department of State Health Services (DSHS) unveiled the amended hemp rules on Friday, about two months after publishing proposed regulations with licensing fees and other changes that led organizations such as the Texas Cannabis Policy Center (TCPC) to sound the alarm. In response, the department received more than 1,400 comments urging revisions. “Revised rules have slashed manufacturer fees from $25,000 to $10,000 and retailer fees from $20,000 to $5,000. This is a direct victory for advocacy,” Heather Fazio, director of TCPC, said in an email to supporters on Monday. “However, significant challenges remain.” Specifically, the agency decided to maintain language requiring hemp products to be tested for “total THC” content, including THCA, which means most cannabis flower would be considered non-compliant with limitations imposed under state law. “We estimate this will hand 50 percent of the legal market to illicit operators, making our state less safe,” Fazio said. TCPC and other groups such as the Texas Hemp Business Council (THBC) have also pointed out that there would be additional requirements imposed on hemp businesses with respect to product testing, labeling and record-keeping. The Texas Department of State Health Services has adopted new rules for consumable hemp products under Chapter 300. Key takeaways from our initial review: • Manufacturer licenses: $10,000 per facility • Retail licenses: $5,000 per location • THCA now included in total THC… — Texas Hemp Business Council (@TexasHempBiz) March 7, 2026 Separately, under a proposed rule from the Texas Alcoholic Beverage Commission (TABC) there would also be a “less consequential, but important” update to the hemp program, Fazio said, with the agency seeking to prohibit the on-site consumption of hemp at businesses where alcohol isn’t allowed. There would be no “sampling” exceptions in place, either. (Disclosure: Fazio supports Marijuana Moment’s work with a monthly Patreon pledge.) TCPC did share a piece of positive news for advocates, noting “steady progress” in expanding the state’s medical cannabis program under a law enacted last year. While adult-use legalization has continued to stall in the conservative legislature, the medical marijuana program is significantly expanding, with nine new licenses already approved and three more expected before April 1. Meanwhile, last week, Texas voters approved a marijuana legalization question that appeared on the state’s Democratic primary ballot. As part of the primary election on Tuesday, each major party was able to place several non-binding propositions on the ballot that allow voters show how they feel on key issues. The Texas Democratic Party used one of its propositions to find out where the electorate stands on legalizing cannabis and whether past convictions should be expunged. For what it’s worth, a statewide poll released last month found that Texas voters don’t like how state leaders and lawmakers have handled marijuana and THC policy issues. In the survey, a plurality of voters (40 percent) said they disapprove of how their elected officials have approached the issue, according to the survey. Just 29 percent said they approve of how cannabis issues have been handled, while 31 percent said they didn’t have an opinion one way or another. A separate poll released last year found that a plurality of Texas voters want the state’s marijuana laws to be made “less strict.” And among the legislative items lawmakers considered during recent special sessions, voters say a proposal to address hemp regulations was among the least important. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — For its part, the state Department of Public Safety in October adopted additional rules to increase the number of licensed dispensaries, establishing security requirements for “satellite” locations and authorizing the revocation of licenses for certain violations. DSHS also recently finalized rules allowing doctors to recommend new qualifying conditions for cannabis patients and creating standards for allowable low-THC inhalation devices. Meanwhile, bipartisan Texas lawmakers say the stage is set to advance legislation next session establishing regulations for hemp THC products, with growing understanding among their colleagues that prohibition fails to effectively address concerns about the cannabis market. The post Texas Officials Unveil Amended Hemp Rules With Strict ‘Total THC’ Limits But Lower Licensing Fee Than Previously Floated appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia lawmakers have passed a bill to protect the rights of parents who use marijuana in compliance with state law. The legislation from Del. Nadarius Clark (D) cleared both the Senate and House of Delegates last week in amended form. It now heads to Gov. Abigail Spanberger (D). The bill is consistent with a measure Clark sponsored last session that advanced through the legislature, only to be vetoed by then-Gov. Glenn Youngkin (R). The current proposal states that a “person’s legal possession or consumption of substances…alone shall not serve as a basis to restrict custody or visitation unless other facts establish that such possession or consumption is not in the best interest of the child.” The bill also specifies that a parent or legal guardian can’t be construed to have failed a drug test over legal substances such as cannabis. “HB 942 is a bill that states no parent shall lose their child custody or visitation for the sole legal possession or consumption of authorized substances,” Clark said on the House floor on Friday when urging the body to approve the Senate’s changes to his legislation. “The Senate put a substitution on this bill because there’s a current study going on a certain part of the code section, so we didn’t want to touch that until the study is complete.” Youngkin, the former governor, claimed in his veto message last year that the prior measure introduced “unnecessary complications and risks exposing children to harm.” “The bill disregards clear evidence linking substance use to child endangerment, particularly in the wake of increased incidents of children ingesting cannabis-infused substances following the legalization of marijuana,” he argued. “By broadly prohibiting courts from considering parental marijuana use in custody and visitation determinations, [the bill] risks prioritizing drug use over the health and well being of children.” The then-governor also vetoed an even earlier version of the bill in 2024. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — While Spanberger, the current governor, hasn’t specifically weighed in on the parental rights legislation, she is generally more supportive of marijuana reform than her predecessor and backs legalizing recreational cannabis sales, which Youngkin also vetoed. Legislation to legalize and regulate the adult-use marijuana market is also advancing toward the governor’s desk this session. The House and Senate passed differing versions of the reform and a bicameral conference committee has been appointed to negotiate a single proposal to send to Spanberger. Virginia lawmakers have additionally sent the governor legislation to provide a pathway to resentencing for people with prior marijuana convictions. Legislation to allow patients to access medical cannabis in hospitals is also set for Spanberger’s action. The post Virginia Bill To Protect Rights Of Parents Who Use Marijuana Heads To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net